4.7 Article

VARIATIONS IN TARGET VOLUME DEFINITION FOR POSTOPERATIVE RADIOTHERAPY IN STAGE III NON-SMALL-CELL LUNG CANCER: ANALYSIS OF AN INTERNATIONAL CONTOURING STUDY

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2009.02.072

Keywords

Non-small-cell lung cancer; Resection; Postoperative radiotherapy; Target volumes; Interobserver variability

Ask authors/readers for more resources

Purpose: Postoperative radiotherapy (PORT) in patients with completely resected non small-cell lung cancer with mediastinal involvement is controversial because of the failure of earlier trials to demonstrate a survival benefit. Improved techniques may reduce toxicity, but the treatment fields used in routine practice have not been well studied. We studied routine target volumes used by international experts and evaluated the impact of a contouring protocol developed for a new prospective study, the Lung Adjuvant Radiotherapy Trial (Lung ART). Methods and Materials: Seventeen thoracic radiation oncologists were invited to contour their routine clinical target volumes (CTV) for 2 representative patients using a validated CD-ROM based contouring program. Subsequently, the Lung ART study protocol was provided, and both cases were contoured again. Variations in target volumes and their dosimetric impact were analyzed. Results: Routine CTVs were received for each case from 10 clinicians, whereas six provided both routine and protocol CTVs for each case. Routine CTVs varied up to threefold between clinicians, but use of the Lung ART protocol significantly decreased variations. Routine CTVs in a postlobectomy patient resulted in V(20) values ranging from 12.7% to 54.0%, and Lung ART protocol CTVs resulted in values of 20.6% to 29.2%. Similar results were seen for other toxicity parameters and in the postpneumectomy patient. With the exception of upper paratracheal nodes, protocol contouring improved coverage of the required nodal stations. Conclusion: Even among experts, significant interclinician variations are observed in PORT fields. Inasmuch as contouring variations can confound the interpretation of PORT results, mandatory quality assurance procedures have been incorporated into the current Lung ART study. (C) 2010 Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial

Matthew Van Oirschot, Alanah Bergman, Wilko F. A. R. Verbakel, Lucy Ward, Isabelle Gagne, Vicky Huang, Nick Chng, Peter Houston, Kerry Symes, Christopher G. Thomas, Parminder Basran, David Bowes, Stephen Harrow, Robert Olson, Suresh Senan, Andrew Warner, David A. Palma, Stewart Gaede

Summary: This study assessed the association between target coverage compromise and patient outcomes in SABR treatment for oligometastases. The results showed that for some lesions, a reduction in dose or target coverage was necessary to meet organ at risk constraints. However, target coverage was not significantly associated with survival outcomes or lesional control.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Article Oncology

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Ozguroglu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia

Summary: The study examined the efficacy of consolidation durvalumab in patients with non-small-cell lung cancer, showing significant improvements in overall survival and progression-free survival, with manageable safety. The 5-year follow-up data continued to demonstrate the positive effects of durvalumab on survival and disease progression.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Editorial Material Oncology

Performing SBRT in the Fly-With-Caution Zone: Are We Heeding the Advice of Daedalus?

Anand Swaminath, Timothy Ritter, Alexander V. Louie, David A. Palma, Matthias Guckenberger, Suresh Senan, Andrea Bezjak, Drew Moghanaki

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Article Oncology

Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period

Claire van Vliet, Chris Dickhoff, Idris Bahce, Anton F. Engelsman, Sayed M. S. Hashemi, Cornelis J. A. Haasbeek, Anna M. E. Bruynzeel, Miguel A. Palacios, Annemarie Becker-Commissaris, Berend J. Slotman, Suresh Senan, Famke L. Schneiders

Summary: This study investigated treatment patterns for adrenal metastases using surgery or SABR at a single institution. The number of patients undergoing SABR doubled since 2016, while the numbers undergoing surgery remained unchanged. Both treatments showed low rates of acute toxicity and similar survival outcomes.

RADIOTHERAPY AND ONCOLOGY (2022)

Article Oncology

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia

Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.

ESMO OPEN (2022)

Editorial Material Oncology

Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization

Andrew G. Shuman, Matti S. Aapro, Benjamin Anderson, Katherine Arbour, Pedro C. Barata, Aditya Bardia, Eduardo Bruera, Bruce A. Chabner, Herbert Chen, Edwin Choy, Pierfranco Conte, Giuseppe Curigliano, Don Dizon, Eileen O'Reilly, Antonio Tito Fojo, Hans Gelderblom, Timothy A. Graubert, Jayne S. Gurtler, Evan Hall, Fred R. Hirsch, Ahmed Idbaih, David H. Ilson, Michael Kelley, Carlo La Vecchia, Heinz Ludwig, Beverly Moy, Hyman Muss, Frans Opdam, Rebecca D. Pentz, Marshall R. Posner, Jeffrey S. Ross, Adrian Sacher, Suresh Senan, Enrique Soto Perez de Celis, Kenneth K. Tanabe, Jan B. Vermorken, Eric Wehrenberg-Klee, Susan E. Bates

Summary: In this editorial, the authors discuss the potential implications of the recent Supreme Court decision in Dobbs v. Jackson Women's Health Organization for patients with cancer, in the context of the difficult decision of whether or not to choose pregnancy termination.

ONCOLOGIST (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Results from the AAPM Task Group 324 respiratory motion management in radiation oncology survey

Helen J. Ball, Lakshmi Santanam, Suresh Senan, James A. Tanyi, Marcel van Herk, Paul J. Keall

Summary: A survey was conducted to assess the clinical practice of respiratory motion management in radiation oncology. The results showed that 84% of respondents used deep inspiration breath hold for left-sided breast cancer. 83% of respondents considered respiratory motion management very important or required for thoracic and abdominal cancer patients. 95% of respondents used respiratory motion management for thoracic and abdominal sites.

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Evaluation of a workflow for cone-beam CT-guided online adaptive palliative radiotherapy planned using diagnostic CT scans

Koen J. Nelissen, Eva Versteijne, Suresh Senan, Daan Hoffmans, Ben J. Slotman, Wilko F. A. R. Verbakel

Summary: A workflow involving preplanning on diagnostic CT imaging and online plan adaption using cone-beam CT scan was developed for single-visit radiotherapy. The study showed that this workflow can meet clinical goals and outperform initial treatment plans based on daily CT scan.

JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Comparison of MR-guided radiotherapy accumulated doses for central lung tumors with non-adaptive and online adaptive proton therapy

Moritz Rabe, Miguel A. Palacios, John van Sornsen R. de Koste, Chukwuka Eze, Martin Hillbrand, Claus Belka, Guillaume Landry, Suresh Senan, Christopher Kurz

Summary: This study compared the accumulated doses of MRgRT, non-adaptive IMPT, and online adaptive IMPT for central lung tumors, with a focus on the bronchial tree dose. The results showed that non-adaptive and online adaptive proton therapy achieved significant dose sparing for organs in close proximity to central lung tumors compared to MRgRT. Online adaptive IMPT achieved significantly lower doses to the bronchial tree compared to MRgRT.

MEDICAL PHYSICS (2023)

Article Oncology

Same-day adaptive palliative radiotherapy without prior CT simulation: Early outcomes in the FAST-METS study

Koen J. Nelissen, Eva Versteijne, Suresh Senan, Barbara Rijksen, Marjan Admiraal, Jorrit Visser, Sarah Barink, Amy L. de la Fuente, Daan Hoffmans, Ben J. Slotman, Wilko F. A. R. Verbakel

Summary: We developed a rapid palliative radiotherapy workflow using diagnostic imaging for pre-planning and on-couch target and plan adaptation based on a synthetic CT obtained from CBCT. The adapted treatment plans showed significant improvements in target coverage compared to the original plans. Most patients were satisfied with the workflow. The average treatment time, including consultation and on-couch adaptive treatment, was 85 minutes.

RADIOTHERAPY AND ONCOLOGY (2023)

Article Oncology

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline

Puneeth Iyengar, Sean All, Mark F. Berry, Thomas P. Boike, Lisa Brad fi Eld, Anne -Marie C. Dingemans, Jill Feldman, Daniel R. Gomez, Paul J. Hesketh, Salma K. Jabbour, Melenda Jeter, Mirjana Josipovic, Yolande Lievens, Fiona Mcdonald, Bradford A. Perez, Umberto Ricardi, Enrico Ruffini, Dirk De Ruysscher, Hina Saeed, Bryan J. Schneider, Suresh Senan, Joachim Widder, Matthias Guckenberger

Summary: This guideline aims to review the use of local therapy in the management of extracranial oligometastatic non-small cell lung cancer (NSCLC) and provide recommendations. Currently, data is limited, but with increasing evidence supporting the use of local therapy in NSCLC, this guideline attempts to provide recommendations based on the quality of available data.

PRACTICAL RADIATION ONCOLOGY (2023)

Article Oncology

Accuracy of deformable image registration-based intra-fraction motion management in Magnetic Resonance-guided radiotherapy

Miguel A. Palacios, Georgi Gerganov, Paul Cobussen, Shyama U. Tetar, Tobias Finazzi, Berend J. Slotman, Suresh Senan, Cornelis J. A. Haasbeek, Iwan Kawrakow

Summary: This study evaluated the accuracy of automatic tumor segmentation in MR-guided radiotherapy (MRgRT) by comparing it to manual delineations performed by experienced observers. The results showed a high level of agreement between automatic segmentation and manual delineation.

PHYSICS & IMAGING IN RADIATION ONCOLOGY (2023)

Article Oncology

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy

Hilal Tekatli, Miguel A. Palacios, Famke L. Schneiders, Cornelis J. A. Haasbeek, Ben J. Slotman, Frank J. Lagerwaard, Suresh Senan

Summary: This study investigated the long-term clinical outcomes of MR-guided SF-SABR on a 0.35 T linac for lung tumors. The results showed that SF-SABR, using automatic beam gating during breath-holds, achieved good tumor control and low toxicity.

RADIOTHERAPY AND ONCOLOGY (2023)

Article Oncology

Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk

Famke L. Schneiders, Claire van Vliet, Nicolas Giraud, Anna M. E. Bruynzeel, Ben J. Slotman, Miguel A. Palacios, Suresh Senan

Summary: This study retrospectively reviewed the outcomes of MR-guided adrenal SABR and found that this approach is well tolerated and achieves high local control rates. Further research using deformable dose accumulation is needed to better understand the dose-response relationship.

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2023)

Article Oncology

Same-day consultation, simulation and lung Stereotactic Ablative Radiotherapy delivery on a Magnetic Resonance-linac

Miguel A. Palacios, Sonja Verheijen, Famke L. Schneiders, Omar Bohoudi, Berend J. Slotman, Frank J. Lagerwaard, Suresh Senan

Summary: The study investigated the clinical feasibility, patient satisfaction, and delivery accuracy of single-fraction MR-guided SABR in a single day. All 10 patients completed the one-stop-shop procedure in a single day and reported satisfaction with the process. The accuracy of SABR delivery was high with little impact of system-latency.

PHYSICS & IMAGING IN RADIATION ONCOLOGY (2022)

No Data Available